U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE * Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

Le A 36 248

INTERNATIONAL APPLICATION NO. PCT/EP2003/009525

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED 10 September 2002 (10.09.2002)

28 August 2003 (23.08.2003) TITLE OF INVENTION PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES APPLICANT(S) FOR DO/EO/US GIELEN-HAERTWIG, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. l An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

Other items or information:

1) Certificate of Mailing under 37 C.F.R. 1.10; 2) Letter of Limited Recognition Under 37 CFR 11.9(b);

20. Other items or information:

21. Other items or information:

22. This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents P.O. Box 1450, Alexandria VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: MAR 1 0 2005 Express Mail Label No.: ED 168 598 298 US

Page 1 of 2

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICA	HOM ME (IF	Known sep :	340 1 30	6) INTERNATIONAL AI	PPLICA	TION NO.	ATTORNEY'S DOC	KET NUMBER
U.S. APPLICATION NO. (IT RECOVERS SEE 32 CER 15) INTERNATIONAL APPLICATION NO. PCT/EP2003/009525						Le A 36	248	
21. The followi	•						Applicant use	Office use only
	ational fee	,			• • • • • • • • • • • • • • • • • • • •	\$300.00	\$ 300.00	
b) Examin	nation fee	***************************************	•••••			. \$200.00	\$ 200.00	
c) Search f	fee	••••••	•••••			.\$500.00	\$ 500.00	
	TOTAL OF	ABOVE CA	LCULATIO	NS =		\$1000.00	\$ 1,000.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each								
additional 5								
Total Sheets	Extra she	Extra sheets		Number of each additional 50 or fraction thereof (round up to a whole number)				
115 - 100 =	100 = 15 /50		1			× \$250.00	\$ 250.00	
Surcharge of \$1: claimed priority of	30.00 for fundate (37 CFF	nishing the o	ath or decla	aration later than 30 months f	from the	earliest	\$	<u> </u>
CLAIMS		NUMBER FIL	LED	NUMBER EXTRA		RATE	\$	
Total claims	ŝ	19 - 20		0		\$50.00	\$ 0.00	
Independent clai	ims	6	- 3 =	3	×	\$200.00	\$ 600.00	
MULTIPLE DEP	ENDENT CL	_AIM(S) (if ar	oplicable)		+	\$360.00	\$	
				TOTAL OF ABOVE			\$ 1,850.00	
Applicant c by 1/2.	laims small e	entity status.	See 37 CFI	R 1.27. The fees indicated at	bove ar	e reduced	\$	
SUBTOTAL =							\$ 1,850.00	
Processing fee o			ne English t	translation later than 30 mont	ths from	n the earliest +	\$	
				TOTAL	L NATIC	ONAL FEE =	\$ 1,850.00	
				1.21(h)). The assignment mu	ust be an	ccompanied +	\$	
TOTAL FEES ENCLOSED =							\$ 1,850.00	
Amount to be refunded:								\$
				Am	ount to	be charged		\$
a. A chec	ck in the amo	ount of \$		to cover the abo	ove fees	s is enclosed.		
b. 🗶 Please								
c. X The Co								
d. Fees ar	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where ar	ın appropriat	ate time limit	under 37 C	CFR 1.495 has not been me on to pending status.			(37 CFR 1.137(a) or (b))	must be filed
SEND ALL CORRESPONDENCE TO: Customer No. 35969							ultein	
Jeffrey M. Greenman Bayer Pharmaceuticals Corporation 400 Morgan Lane West Hoven CT 05516			ion	SIGNATURE				
					_	Tilman Brei	tenstein	
						gnition Under 37 CFR 11	.9(b)	
REGISTRATION NUMBER								

Attorney's Docket No. Le A 36 248

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gielen-Haertwig, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/EP2003/009525

Filed: herewith

For: Pyrimidinone Derivatives as Therapeutic Agents Against Acute and Chronic Inflammatory, Ischaemic and Remodelling Processes

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the attached correspondence comprising:

X	Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];								
×	Application Data Sheet under 37 C.F.R. 1.76;								
×	Preliminary Amendment;								
	Original oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4));								
	English Translation of the Application (35 U.S.C. 371(c)(2));								
×	Copy of the International Application as filed (35 U.S.C. 371(c)(2));								
X	Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein;								
X	Return Receipt Post Card;								
×	Other: Letter of Limited Recognition Under 37 CFR 11.9(b)								

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>ED168598298US</u> addressed to:

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

March 10,2045

Signature of Person Certifying /Tilman Breitenstein

